Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Brokerages Set Neurogene Inc. (NASDAQ:NGNE) Price Target at $44.00
Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
Neurogene CEO Details NGN-401 Rett Trial, FDA Alignment, and Key 2026 Catalysts at Conference
Neurogene to Participate in Stifel 2026 Virtual CNS Forum
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Here Are Friday’s Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More
Neurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
Neurogene Inc. (NASDAQ:NGNE) Receives $44.00 Average Price Target from Analysts
Neurogene Maps NGN-401 Pivotal Rett Timeline, Mid-2026 Data Update at Guggenheim Summit
Neurogene to Participate in Upcoming Investor Conferences
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Analysts Set Neurogene Inc. (NASDAQ:NGNE) Target Price at $42.50
Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome
Neurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene: From Speculation To Execution With NGN-401
Neurogene Reports Third Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Inc. (NGNE) Presents at Stifel 2025 Healthcare Conference Transcript
Neurogene Reports Positive Interim Data in Pediatric Cohort from NGN-401 Gene Therapy Trial for Rett Syndrome
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates
Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting
Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome
Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates
Neurogene to Participate in Upcoming Conferences
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE